Kleveland P M, Haugen S E, Waldum H L
Scand J Gastroenterol. 1985 Jun;20(5):569-76. doi: 10.3109/00365528509089698.
The preparation of 125I-labelled gastrin 1-17, using Iodo-gen as oxidizing agent, is described. Mono-125I-gastrin was purified from the iodination mixture by gel chromatography, followed by ion-exchange chromatography. The Iodo-gen-labelled 125I-gastrin tracer showed a slightly higher immunoreactivity than a similarly purified tracer produced by a gentle chloramine-T method (50% binding of 0.45 fmol tracer at an antibody dilution of 945,000 versus 780,000, respectively). The Iodo-gen-labelled 125I-gastrin, which had the same biological activity as native gastrin when tested in conscious gastric fistula rats, was tested for specific binding at 30 degrees C in pronase-isolated rat gastric fundic cells and plasma membranes from the same area. A specific binding with a Kd of 4.5 X 10(-9) M was found to isolated fundic cells. This binding was rapid and reached equilibrium within 40 min. The dissociation induced by a 10-fold dilution of the incubation medium was biphasic, with a rapid initial phase and a slow late phase, indicating two different binding sites. On the other hand, no reproducible specific binding of the tracer to plasma membranes was obtained. This study shows that Iodo-gen is suitable as an oxidizing agent in iodination of gastrin without loss of biological activity. The tracer produced may be used in receptor studies for isolated cells, whereas the use of plasma membranes for studying gastrin receptors needs reevaluation.
本文描述了使用碘代甘氨酸作为氧化剂制备¹²⁵I标记的胃泌素1 - 17的方法。通过凝胶色谱法从碘化混合物中纯化单¹²⁵I - 胃泌素,随后进行离子交换色谱法。与通过温和氯胺 - T法制备的类似纯化示踪剂相比,碘代甘氨酸标记的¹²⁵I - 胃泌素示踪剂显示出略高的免疫反应性(在抗体稀释度为945,000时,0.45 fmol示踪剂的结合率分别为50%,而氯胺 - T法为780,000)。在清醒胃瘘大鼠中测试时,碘代甘氨酸标记的¹²⁵I - 胃泌素与天然胃泌素具有相同的生物活性,在30℃下对来自同一区域的链霉蛋白酶分离的大鼠胃底细胞和质膜进行特异性结合测试。发现与分离的胃底细胞的特异性结合的解离常数Kd为4.5×10⁻⁹M。这种结合迅速,在40分钟内达到平衡。孵育培养基10倍稀释诱导的解离是双相的,有一个快速的初始阶段和一个缓慢的后期阶段,表明存在两个不同的结合位点。另一方面,未获得示踪剂与质膜的可重复特异性结合。本研究表明,碘代甘氨酸适合作为胃泌素碘化的氧化剂,且不会丧失生物活性。所产生的示踪剂可用于分离细胞的受体研究,而使用质膜研究胃泌素受体需要重新评估。